Myovant Sciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Myovant Sciences (NYSE: MYOV) will host webcasts at two upcoming investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is on February 25, 2021, where CEO David Marek and CFO Frank Karbe will engage in a fireside chat at 3:40 p.m. ET. The Cowen 41st Annual Health Care Conference follows on March 2, 2021, at 11:10 a.m. ET, featuring similar participation from management. Presentations will be available on Myovant's website.

BASEL, Switzerland, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences:

• SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 3:40 p.m. Eastern Time. David Marek, Chief Executive Officer of Myovant Sciences, Inc., and Frank Karbe, President and Chief Financial Officer of Myovant Sciences, Inc., will participate in a fireside chat. Management will also participate in one-on-one investor meetings on February 25.
  
  
• Cowen 41st Annual Health Care Conference on March 2, 2021 at 11:10 a.m. Eastern Time. Mr. Marek and Mr. Karbe will participate in a fireside chat. Management will also participate in one-on-one investor meetings on March 2.

The presentations will be accessible on the Events page under the Investors & Media section of the Myovant website at www.myovant.com.

About Myovant Sciences 
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor Contact:
Ryan Crowe
Vice President, Investor Relations
Myovant Sciences, Inc.
+1 (650) 781-9106
investors@myovant.com

Media Contact:
Albert Liao 
Director, Corporate Communications
Myovant Sciences, Inc.
+1 (650) 410-3055
media@myovant.com

FAQ

What conferences will Myovant Sciences attend in February 2021?

Myovant Sciences will attend the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, and the Cowen 41st Annual Health Care Conference on March 2, 2021.

Who will represent Myovant Sciences at the conferences?

David Marek, CEO, and Frank Karbe, CFO, will represent Myovant Sciences at both investor conferences.

What time will the SVB Leerink Conference presentation occur?

The presentation at the SVB Leerink 10th Annual Global Healthcare Conference is scheduled for 3:40 p.m. Eastern Time on February 25, 2021.

How can investors access Myovant Sciences' presentations?

Investors can access the presentations on the Events page under the Investors & Media section on Myovant's website.

What is the focus of Myovant Sciences?

Myovant Sciences focuses on redefining healthcare for women and men, with a portfolio that includes treatments for advanced prostate cancer and uterine fibroids.